MS Drug Development Agreement Based On WEHI’s Medicinal Chemistry

Research conducted at The Walter and Eliza Hall Institute (WEHI) has contributed significantly to a major licensing agreement signed between Australian biotechnology company, Bionomics, (ASX:BNO) and Germany- based pharmaceutical company, Merck Serono. Under the Development and Licensing Agreement, Merck Serono will seek to develop new treatments for multiple sclerosis (MS) and other autoimmune conditions.

More: continued here

Filed under: Multiple Sclerosis on July 4th, 2008